FDA grants expanded access to the pancreatic cancer drug daraxonrasib

The U.S. Food and Drug Administration (FDA) has granted expanded access for the use of an experimental pancreatic cancer drug, daraxonrasib. This means the drug will be available for early access to those who previously received conventional treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). A health care provider must request access to the medication for their patient, according to an FDA statement.